

Inhibition of demethylases by GSK-J1/J4


ARISING FROM L. Kruidenier *et al. Nature* **488**, 404–408 (2012); doi:10.1038/nature11262

The recent publication¹ of the first highly potent and specific inhibitor GSK-J1/J4 of the H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A provides a potential tool compound for this histone demethylase subfamily¹. This inhibitor was used in tissue culture assays to conclude that the catalytic activities of the KDM6 proteins are required in inflammatory responses¹; the generation of the inhibitor is intriguing, because it provides a strategy for generating sub-type-specific inhibitors of the 27-member jumonji family and for the future treatment of various types of disease^{2–6}. Here we show that the inhibitor is not specific for the H3K27me3/me2-demethylase subfamily *in vitro* and in tissue culture assays. Thus, the inhibitor cannot be used alone for drawing conclusions regarding the specific role of H3K27me3/me2-demethylase

activity in biological processes or disease. There is a Reply to this Brief Communications Arising by Kruidenier, L. *et al. Nature* **514**, http://dx.doi.org/10.1038/nature13689 (2014).

The jumonji demethylases are dependent on two cofactors, 2-oxoglutarate (also known as α -ketoglutarate) and Fe^{2+} for enzymatic activity. The compound published by Kruidenier *et al.*¹, GSK-J1 is a competitive inhibitor of the two cofactors, but not of the substrate, with a half-maximum inhibitory concentration (IC_{50}) of 60 nM towards KDM6B as measured in an AlphaScreen assay. By performing *in vitro* assays on a number of other jumonji demethylases, including the closely related JMJD2/KDM4 subfamily and 160 other proteins, Kruidenier *et al.*¹ concluded that GSK-J1 is specific for the KDM6 subfamily. However, we noted that GSK-J1 was not tested on the JARID1/KDM5 subfamily, which contains the four demethylases with the closest homology in the catalytic domain to KDM6B and KDM6A (ref. 3). As shown in Fig. 1a, b, we tested the inhibitory activity of GSK-J1 towards 12 different jumonji demethylases. In agreement with the published data¹, our results show that GSK-J1 is a highly potent inhibitor of KDM6B and KDM6A. Moreover, and also in agreement with Kruidenier *et al.*¹, the other tested demethylases, except for KDM5B and KDM5C, were only marginally or not significantly inhibited *in vitro*. However, our results show that GSK-J1 only is fivefold to tenfold more potent towards KDM6B and KDM6A as compared to KDM5B and KDM5C. As a control for these experiments, we used GSK-J2, an isomer of GSK-J1 that does not have any specific activity¹. Taken together, these results show that GSK-J1 is a potent inhibitor of jumonji proteins with activity towards H3K27me3/me2 (KDM6) and H3K4me3/me2 (KDM5) *in vitro*.

The highly polar GSK-J1 compound is restricted from entering into cells, and Kruidenier *et al.*¹ therefore changed the acid group in GSK-J1 and GSK-J2 to an ester, thereby generating GSK-J4 and GSK-J5, respectively¹. In a mass-spectrometry based *in vitro* assay, GSK-J4 was shown to have an $\text{IC}_{50} > 50 \mu\text{M}$ ¹. In a more sensitive AlphaLISA assay, we found that GSK-J4 has half-maximum inhibitory concentration (IC_{50}) towards KDM6B and KDM6A of 8.6 μM and 6.6 μM , respectively (Fig. 1b). GSK-J4 was also found to inhibit the catalytic activity of the other tested demethylases with similar potency (Fig. 1b). Kruidenier *et al.*¹ did not report on the IC_{50} value of GSK-J4 towards different jumonji demethylases in transfected cells, however, they showed an IC_{50} value of 9 μM towards the production of $\text{TNF-}\alpha$ in lipopolysaccharide-stimulated macrophages. We tested the inhibitory effect of the four GSK compounds in cells transfected with KDM6B, KDM5B and KDM4C, respectively, and as shown in Fig. 1c, d, GSK-J4 shows very similar IC_{50} values towards the 3 demethylases, representing 3 different subfamilies. Taken together, our results show that GSK-J1 and GSK-J4 inhibit demethylases in addition to KDM6B and KDM6A. Therefore, this compound cannot be used alone for demonstrating a role for H3K27 demethylation in biological processes.



Enzyme	Enzymatic assays, IC_{50} (M)			
	GSK-J1	GSK-J2	GSK-J4	GSK-J5
KDM2B	2.1×10^{-5}	8.3×10^{-6}	2.1×10^{-6}	2.4×10^{-5}
KDM3A	$> 7.5 \times 10^{-5}$ *	$> 1.0 \times 10^{-4}$ *	8.5×10^{-6} *	$> 1.0 \times 10^{-4}$ *
KDM3B	$> 7.5 \times 10^{-5}$	$> 1.0 \times 10^{-4}$ *	6.9×10^{-6} *	$> 1.0 \times 10^{-4}$ *
KDM4A	$> 5.0 \times 10^{-5}$	$> 1.0 \times 10^{-4}$ *	7.5×10^{-6} *	$> 1.0 \times 10^{-4}$ *
KDM4B	7.3×10^{-5}	$> 1.0 \times 10^{-4}$ *	3.8×10^{-6} *	$> 1.0 \times 10^{-4}$ *
KDM4C	3.4×10^{-5}	$> 1.0 \times 10^{-4}$	5.5×10^{-6}	$> 1.0 \times 10^{-4}$
KDM5A	6.8×10^{-6} *	$> 2.0 \times 10^{-5}$ *	ND	$> 5.0 \times 10^{-5}$ *
KDM5B	1.7×10^{-7}	3.3×10^{-5}	9.7×10^{-6}	$> 2.5 \times 10^{-5}$
KDM5C	5.5×10^{-7}	$> 7.5 \times 10^{-5}$ *	1.5×10^{-5}	$> 1.0 \times 10^{-4}$ *
KDM6A	5.3×10^{-8}	$> 1.0 \times 10^{-4}$	6.6×10^{-6}	$> 1.0 \times 10^{-4}$
KDM6B	2.8×10^{-8}	4.9×10^{-5} *	8.6×10^{-6} *	$> 1.0 \times 10^{-4}$ *
PHF8	2.8×10^{-5} *	1.7×10^{-5} *	4.2×10^{-6}	$> 2.5 \times 10^{-5}$

$n = 3$ unless otherwise specified. * $n = 2$.

Enzyme	Cell based assays, IC_{50} (M)			
	GSK-J1	GSK-J2	GSK-J4	GSK-J5
KDM4C	ND	ND	7.3×10^{-6}	$> 1.0 \times 10^{-5}$ *
KDM5B	ND	ND	3.1×10^{-6}	$> 1.0 \times 10^{-5}$ *
KDM6B	1.7×10^{-5} *	$> 1.0 \times 10^{-4}$ *	3.1×10^{-6}	$> 2.5 \times 10^{-5}$

$n = 2$ unless otherwise specified. * $n = 1$.

Figure 1 | GSK-J1/J4 inhibition of several histone demethylase subfamilies.

a, Assessment of the inhibitory potential of GSK-J1 towards the indicated jumonji enzymes by AlphaLISA based assays. **b**, Inhibitory potential of GSK-J1, GSK-J2, GSK-J4 and GSK-J5 towards the indicated enzymes as assessed by AlphaLISA based assays. IC_{50} values are indicated as means. The deviation of the mean was always less than twofold. ND, not determined. n equals the number of replicates. **c**, Assessment of inhibitory potential of GSK-J4 in cell-based assays in which the indicated enzymes were transfected, and their activity measured by induced loss of H3K27me2 (KDM6B), H3K4me2 (KDM5B) and H3K9me3 (KDM4C). **d**, Inhibitory activity of the indicated compounds towards the indicated enzymes in cell-based assays. IC_{50} values are indicated as mean, and the deviation from the mean was always less than twofold. ND, not determined.

Methods

AlphaLISA assays were essentially performed as described in the protocol provided by the manufacturer (PerkinElmer). The enzymes used were: KDM2B (amino acids 1–650), KDM3A (amino acids 2–1,322), KDM3B (amino acids 842–1,761), KDM4A (amino acids 1–350), KDM4B (amino acids 2–500), KDM4C (amino acids 1–349), KDM5A (amino acids 1–1,090), KDM5B (amino acids 1–809), KDM5C (amino acids 2–1,560), KDM6A (amino acids 919–1,401), KDM6B (amino acids 1,043–1,643), and PHF8 (amino acids 1–1,024). Substrates and assay conditions can be provided upon request.

To measure the inhibitory activity of the tested compounds in cell-based assays, U2OS cells were transfected with epitope tagged versions of KDM6B (amino acids

1,026–1,682), KDM5B (amino acids 1–752) or full length KDM4C. Transfected cells were incubated with the indicated concentration of compounds, and the activity of the demethylase towards substrate in transfected cells was measured using antibodies specific for H3K27me2 (Abcam Ab24684), H3K4me2 (Milipore 07-030) and H3K9me3 (Abcam Ab8898).

Bo Heinemann¹, Jesper Morten Nielsen¹, Heidi Rye Hudlebusch¹, Michael J. Lees², Dorthe Vang Larsen¹, Thomas Boesen¹, Marc Labelle¹, Lars-Ole Gerlach¹, Peter Birk¹ & Kristian Helin^{2,3,4}

¹EpiTherapeutics Aps, Ole Maaløes Vej 3, 2200 Copenhagen, Denmark.

²Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark.

³Centre for Epigenetics, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark.

⁴The Danish Stem Cell Center (DanStem), University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark.

email: kristian.helin@bric.ku.dk

Kruidenier *et al.* reply

REPLYING TO B. Heinemann *et al.* *Nature* **514**, <http://dx.doi.org/10.1038/nature13688> (2014)

We welcome the accompanying Comment¹ by Heinemann *et al.*, in which the authors use an extensive panel of sensitive KDM assays to independently confirm our results² that GSK-J1 is a potent KDM6 inhibitor. Additionally, Heinemann *et al.*¹ demonstrate that GSK-J1 has some, albeit weaker, activity towards KDM5B and KDM5C, for which we only had preliminary data available at the time of our original publication. As our jumonji assay portfolio expands, we have continued to update the GSK-J1 activity profile on the SGC website (<http://www.thesgc.org/chemical-probes/GSKJ1>); this includes KDM5 inhibition activity by GSK-J1 similar to that reported by Heinemann. In conclusion, GSK-J1 remains the most selective KDM inhibitor yet disclosed and thus a valuable chemical tool.

Heinemann *et al.*¹ also show a broader, weak micromolar KDM inhibitory activity of the ester pro-drug version of GSK-J1, GSK-J4. GSK-J4 is not itself a chemical tool for direct KDM inhibition, but was designed specifically to enable efficient intracellular delivery of GSK-J1 into macrophages. In our work, the intracellular conversion of ester pro-drug is complete within 15 min after which levels of intracellular GSK-J4 are negligible ([GSK-J4] = 150 nM; [GSK-J1] = 11.8 μM). This renders the activity profile of GSK-J4 irrelevant and the biological effects in macrophages will be exclusively driven by the activity of GSK-J1. For other cell systems, it is essential to assess the ability to convert GSK-J4 to GSK-J1 before conducting and interpreting biological studies.

Despite the refinement of the selectivity profile of GSK-J1, our conclusion that KDM6 enzymatic activity is a key determinant of lipopolysaccharide responses in macrophages stands and was independently verified using short interfering RNA (siRNA) mediated knockdown of KDM6 enzymes. GSK-J1 remains a useful chemical probe for studying the catalytic function of KDM6 and the additional KDM5 activity may provide new opportunities for its use.

Received 23 January; accepted 25 June 2014.

1. Kruidenier, L. *et al.* A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. *Nature* **488**, 404–408 (2012).
2. Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. *Nature* **502**, 480–488 (2013).
3. Kooistra, S. M. & Helin, K. Molecular mechanisms and potential functions of histone demethylases. *Nature Rev. Mol. Cell Biol.* **13**, 297–311 (2012).
4. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. *Nature Rev. Drug Discov.* **11**, 384–400 (2012).
5. Greer, E. L. & Shi, Y. Histone methylation: a dynamic mark in health, disease and inheritance. *Nature Rev. Genet.* **13**, 343–357 (2012).
6. Højfeldt, J. W., Agger, K. & Helin, K. Histone lysine demethylases as targets for anticancer therapy. *Nature Rev. Drug Discov.* **12**, 917–930 (2013).

Author Contributions B.H., J.M.N. and H.R.H. contributed equally to this manuscript. B.H., J.M.N., H.R.H., M.J.L. and D.V.L. performed experiments and analysed data. T.B., M.L., L.-O.G., P.B. and K.H. analysed data. K.H. wrote the manuscript with input from the other authors.

Competing Financial Interests B.H., J.M.N., H.R.H., D.V.L., T.B., M.L., L.-O.G. and P.B. are employees of EpiTherapeutics Aps. K.H. is a co-founder, stockowner and consultant of EpiTherapeutics Aps. M.J.L. has no competing interests to declare.

doi:10.1038/nature13688

Laurens Kruidenier¹, Chun-wa Chung², Zhongjun Cheng³, John Liddle¹, KaHing Che^{4,5}, Gerard Joberty⁶, Marcus Bantscheff⁶, Chas Bountra⁴, Angela Bridges², Hawa Diallo¹, Dirk Eberhard⁶, Sue Hutchinson², Emma Jones², Roy Katso², Melanie Leveridge², Palwinder K. Mander¹, Julie Mosley², Cesar Ramirez-Molina¹, Paul Rowland², Christopher J. Schofield⁴, Robert J. Sheppard¹, Julia E. Smith¹, Catherine Swales⁵, Robert Tanner², Pamela Thomas², Anthony Tumber⁴, Gerard Drewes⁶, Udo Oppermann^{4,5}, Dinshaw J. Patel³, Kevin Lee^{1,†} & David M. Wilson¹

¹Epinova DPU, Immuno-Inflammation Therapy Area, GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK.

²Platform Technology and Science, GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK.

email: chun-wa.h.chung@gsk.com

³Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

⁴Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Headington OX3 7DQ, UK.

⁵Botnar Research Centre, NIHR Biomedical Research Unit, University of Oxford OX3 7LD, UK.

⁶Cellzome AG, Meyerhofstrasse 1, 69117 Heidelberg, Germany.

†Present address: Pfizer, Biotherapeutics R&D, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, USA.

1. Heinemann, B. *et al.* Inhibition of demethylases by GSK-J1/J4. *Nature* **514**, <http://dx.doi.org/10.1038/nature13688> (2014).
2. Kruidenier, L. *et al.* A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. *Nature* **488**, 404–408 (2012).

doi:10.1038/nature13689